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Abstract
Background: In recent years the role of vitamin D status in early life on the development of allergic disease has
generated much interest. The aim of this study was to determine whether cord blood vitamin D concentrations
were associated with risk of early childhood allergic disease.
Methods: Measurements of cord blood 25-hydroxyvitamin D [25(OH)D] concentrations were available in 270
mother-child pairs who were participating in the allergy follow-up (n = 706) of the Docosahexaenoic Acid to
Optimise Mother Infant Outcome randomised controlled trial. All of the children had a hereditary risk of allergic
disease. The diagnosis of allergic disease was made during medical assessments at 1 and 3 years of age.
Results: The mean (standard deviation) standardised cord blood 25(OH)D concentration was 57.0 (24.1) nmol/L.
The cumulative incidence of eczema to 3 years of age, n = 101/250 (40 %) was associated with standardised cord
blood 25(OH)D concentration, with a 10 nmol/L rise in 25(OH)D concentration reducing the risk of eczema by
8 % (relative risk 0.92, 95 % confidence interval 0.86–0.97; P = 0.005). This association was stronger at 1 year of
age, when a 10 nmol/L rise in standardised cord blood 25(OH)D concentration reduced the risk of eczema by
12 % (relative risk 0.88, 95 % confidence interval 0.81–0.96; P = 0.002). No associations between cord blood 25(OH)D
concentrations and development of allergic sensitisation, allergic rhinitis or asthma in early childhood were found.
Conclusion: In children with a family history of allergic disease, a higher cord blood 25(OH)D concentration appears to
be associated with reduced risk of eczema in early childhood.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12610000735055 (DOMInO trial:
ACTRN12605000569606).
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Background
Vitamin D is well known for its role in bone metabolism,
however in recent years, the effects of vitamin D on im-
mune function and the development of allergic disease has
generated much interest. Some epidemiological studies
have shown that lower maternal vitamin D dietary intakes
during pregnancy increases the risk of allergic disease;
atopic dermatitis/eczema [1], food allergen sensitisation
[2], asthma [3] and allergic rhinitis [3] in the offspring.
Studies to date investigating the associations between ob-
jective measures of maternal vitamin D status during preg-
nancy and allergic disease outcomes in childhood have
been limited. Three recent studies [4–6] have found that
higher cord blood vitamin D concentrations were protect-
ive against the development of early childhood atopic
dermatitis/eczema, respiratory tract infection and wheezing,
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but not asthma or allergic rhinitis. However childhood
allergy outcomes in these three studies [4–6] relied on
parent reported history of doctor diagnosed outcomes ra-
ther than direct standardised medical practitioner clinical
assessments.
The best indicator of vitamin D status is considered
to be the measurement of serum 25-hydroxyvitamin
D (25(OH)D), which is the most abundant and stable
vitamin D metabolite [7]. Serum 25(OH)D concentra-
tions reflect vitamin D produced from sunlight exposure
and intake from foods and supplements. It has been well
established that serum 25(OH)D concentrations ≥ 50 nmol/
L facilitate optimal bone health (calcitropic function of
vitamin D) [8]. However in recent years there has been
much discussion about the ideal serum 25(OH)D concen-
trations needed for other health outcomes, with suggestions
[9] that concentrations ≥ 75 nmol/L may be needed for
optimal immune function and for reducing the risk of
allergic disease. During pregnancy, the fetus is exposed to
vitamin D through the cord blood supply and the ability of
25(OH)D to cross the placenta [10]. Cord blood 25(OH)D
concentrations are highly correlated with infant [11, 12]
and maternal serum 25(OH)D concentrations [11, 12],
although they are usually lower compared with maternal
concentrations [13–15].
This paper reports the associations between cord
blood 25(OH)D concentrations and standardised clinic-
ally assessed allergic disease outcomes to 3 years of age
in children with a family history of allergic disease, whose
mothers participated in a double-blinded, multi-centre
randomised controlled trial of omega-3 long-chain poly-
unsaturated fatty acids supplementation in pregnancy
[16–18].
Methods
Subjects and study design
Children (n = 706) who had a mother, father or sibling
with a history of medically diagnosed allergic disease,
and whose mothers were participants in the Docosahex-
aenoic Acid (DHA) to Optimise Mother Infant Outcome
(DOMInO) Trial [16], participated in the allergy follow-
up study of the DOMInO Trial [17, 18]. Briefly, in the
DOMInO trial women allocated to the omega-3 long
chain polyunsaturated fatty acid group were asked to
consume three 500 mg capsules of fish oil concentrate,
providing 800 mg of DHA and 100 mg of eicosapenta-
enoic acid (EPA). Women in the control group were
asked to take three 500 mg vegetable oil capsules with-
out omega-3 long chain polyunsaturated fatty acids daily.
Neither of these capsules (intervention or control group)
contained vitamin D. Women took capsules from 21 weeks’
gestation until delivery. Among the 706 child participants
in the allergy follow-up study, measurements of cord blood
25(OH)D concentrations were available in 270 mother-
child pairs. Approval for this study was granted by the
Human Research Ethics Committees of the Women’s
and Children’s Hospital and Flinders Medical Centre,
Adelaide, Australia.
Measurement of cord blood 25(OH)D concentration
Samples of umbilical cord blood were collected at birth.
Plasma was separated from whole blood by centrifugation
and immediately stored at −20 °C. Samples were shipped
to the Steroid and Immunobiochemistry Laboratory
(Christchurch, New Zealand) on dry ice. Analysis of
25(OH)D was conducted using a liquid chromatography-
tandem mass spectroscopy (LC-MS/MS) method [19].
Accuracy of the method was assessed using Standard Refer-
ence Material® 972 from the National Institute of Standards
and Technology (NIST). We determined 25(OH)D3 con-
centrations in levels 1, 2, and 3 of the Standard Reference
Material® 972 to be 60 nmo/L, 30 nmo/L, and 47 nmol/L,
respectively, compared with the NIST Certified Concentra-
tion Values of 60 nmol/L, 31 nmol/L and 46 nmol/L,
respectively. The precision of the method was 6–7 % and
was established by repeat (n = 16) measurements of three
control serum samples 25(OH)D status with concentrations
of 23 nmol/L, 59 nmol/L and 107 nmol/L. 25(OH)D con-
centrations are presented as nmol/L.
Early childhood allergic disease outcome assessments
and definitions
Children participating in the allergy follow-up of the
DOMInO Trial attended a medical review appointment at
1 and 3 years of age [17, 18]. Allergic sensitisation was de-
fined as a positive skin prick test (weal ≥3 mm above nega-
tive control) to at least one of the food allergens (hens’ egg,
cows’ milk, wheat, tuna, peanut, cashew nut and sesame
seed) or aeroallergens (ryegrass pollen, olive tree pollen,
Alternaria tenuis, cat hair and house dust mites -Dermato-
phagoides pteronyssinus and Dermatophagoides farinae)
assessed. Eczema was defined as the presence of eczema,
criteria according to Hanifin and Rajka [20], on medical re-
view or a history of an itchy rash distributed to the facial,
flexural, or extensor surface of the skin that had followed a
fluctuating or chronic course. IgE-associated food allergy
was defined as a history of ingestion of a food with imme-
diate reaction (< 60 min), including skin rash (hives, rash,
or swelling) with or without respiratory symptoms (cough,
wheeze, stridor), gastrointestinal symptoms (abdominal
pain, vomiting, loose stools), or cardiovascular symptoms
(collapse), coupled with sensitisation to the implicated
food. Asthma was defined as a history of 3 or more epi-
sodes of wheeze with the episodes less than 6 weeks apart
and/or daily use of asthma medication. Allergic rhinitis
was defined as a history of sneezing, or a runny, or blocked
nose accompanied by itchy-watery eyes when there have
not been symptoms to suggest an upper respiratory tract
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infection. Respiratory tract infections were defined as a
parent reported history of medically diagnosed bronchio-
litis or Respiratory Syncytial Virus.
Statistical methods
25(OH)D concentrations were standardised to account for
variability in cord blood 25(OH)D by month of birth.
Firstly, an overall weighted mean 25(OH)D concentration
was calculated by weighting individual measurements by
the inverse of the total number of measurements in the
corresponding month (to account for variation in the
number of observations in different months). Secondly,
the residuals from a regression model of 25(OH)D on
month (treated as a categorical variable) were added to
the overall mean 25(OH)D concentration to create stan-
dardised 25(OH)D concentrations. A similar approach
was used by Jenab et al. [21].
For all allergy outcomes, log binomial regression
models were used to estimate the effect of a 10 nmol/L
increase in standardised 25(OH)D on the risk of allergy.
All associations were described using relative risks with
95 % confidence intervals. Statistical models were ad-
justed for the following potential confounders; DHA
treatment group, parity, sex and maternal smoking dur-
ing or leading up to pregnancy. The confounders were
determined a priori based on previous research showing
they are commonly associated with the development of
atopic disease [22]. To avoid over-fitting statistical models
to outcomes with relatively low incidence, only a limited
number of potential confounders were considered prior to
analysis. For outcomes where it was not possible to
achieve model convergence with adjustment for covari-
ates, results of unadjusted models are presented. Since
data were obtained from a randomised trial, effect modifi-
cation of 25(OH)D by DHA treatment group was also
investigated by adding interaction effects to statistical
models. Checks were performed to ensure adequate model
fit throughout, with modified Hosmer-Lemeshow tests
suggesting that the inclusion of standardised 25(OH)D as
a continuous predictor was reasonable for all the allergy
outcomes considered. Statistical significance was assessed
at the two sided P < 0.05 level. All analyses were per-
formed using SAS version 9.3.
Results
The sample of 270 mother-child pairs with available
measurements of cord blood 25(OH)D concentrations
were representative of the overall allergy follow-up study
population (see Table 1).
Vitamin D
The mean (SD) raw cord blood 25(OH)D concentration
was 55.9 (28.4) nmol/L and the mean (SD) standardised
25(OH)D concentration was 57.0 (24.1) nmol/L. The distri-
bution of cord blood standardised 25(OH)D concentrations
are displayed in Fig. 1. Characteristics of the participants
and standardised 25(OH)D concentrations are shown in
Table 2. Standardised 25(OH)D concentrations were
higher for Caucasian mothers (n = 256) with mean (SD) of
58.1 (24.1) nmol/L compared to non-Caucasian mothers
(n = 14) with mean (SD) of 37.8 (14.7) nmol/L, P = 0.002.
For other participant characteristics that may potentially
play a role in allergic disease development, DHA supple-
mentation, maternal smoking, parity and infant sex, the
standardised 25(OH)D concentrations did not differ be-
tween groups.
Early childhood allergic disease outcomes
Overall the cumulative incidence of any allergic disease
(eczema, IgE-mediated food allergy, allergic rhinitis and/
Table 1 Comparison of baseline characteristics between those with cord blood vitamin D (25 (OH) D) concentration results and
total allergy follow-up cohort
Characteristic Vitamin D Cohort (n = 270) Total Cohort (n = 706)
Mother’s age at trial entry (years) a 28.8 (5.6) 29.5 (5.7)
Race – Caucasian 256 (94.8) 672 (95.2)
Mother completed secondary education 171 (63.3) 454 (64.3)
Mother smoked during or leading up to pregnancy 73 (27.0) 205 (29.0)
Primiparous 110 (40.7) 281 (39.8)
Maternal history of allergic disease 182 (67.4) 493 (69.8)
Dual parental history of allergic disease 72 (26.7) 206 (29.2)
Infant sex (male) 129 (47.8) 337 (47.7)
Treatment group
DHA 130 (48.1) 368 (52.1)
Control 140 (51.9) 338 (47.9)
Values are numbers (percentages) unless indicated otherwise
DHA Docosahexaenoic acid
a Mean (± SD)
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or asthma) by 3 years of age was 57 % (137/240) in this
cohort (with a family history of allergic disease). Consist-
ent with the usual pattern of expression of the allergic
phenotype, eczema was the most common allergic dis-
ease in the first three years of life [23], with a cumulative
incidence of 40 % (101/250).
There was no evidence for effect measure modifica-
tion by DHA treatment group in any of the allergic
disease outcomes, so interaction effects were not in-
cluded in the final models. The risk of eczema at 1 year
of age decreased as cord blood 25(OH)D concentration
increased; a 10 nmol/L rise in standardised cord blood
25(OH)D concentration was associated with a 12 %
reduction in risk (relative risk 0.88, 95 % confidence
interval 0.81–0.96; P = 0.002 (Table 3). The cumulative in-
cidence of eczema to 3 years of age was also associated
with cord blood 25(OH)D concentration, with a 10 nmol/
L rise in standardised cord blood 25(OH)D concentration
reducing the risk by 8 % (relative risk 0.92, 95 % confi-
dence interval 0.86–0.97; P = 0.005). A similar relationship
was observed for eczema at 3 years of age, however the
association did not reach statistical significance (Table 3).
The cumulative incidence of eczema with sensitisation
by 3 years of age was also associated with cord blood
25(OH)D concentration, with a 10 nmol/L rise in stan-
dardised cord blood 25(OH)D concentration reducing
the risk by 17 % (relative risk 0.83, 95 % confidence
interval 0.72–0.96; P = 0.01). We also observed a reduc-
tion in the risk, which did not reach statistical signifi-
cance, for eczema with sensitisation at 1 year of age and
at 3 years of age (Table 3).
Medical diagnosis of IgE-mediated food allergy at
1 year of age was uncommon in this cohort, only being
identified in 4/260 (1.5 %) children. The risk of IgE-
mediated food allergy at 1 year of age (but not at 3 years
of age) also decreased as cord blood 25(OH)D concen-
tration increased (Table 3). No associations between
cord blood 25(OH)D concentrations and risk of devel-
opment of allergic sensitisation, allergic rhinitis, asthma
or respiratory tract infections in early childhood were
found (Table 3).
In exploratory analyses, we examined whether the
effect of standardised vitamin D on the allergic disease
outcomes was modified by mother’s smoking status, cat
ownership or dog ownership. As the majority of the
participants were breastfed and of Caucasian race, we
did not examine effect modification by breastfeeding
status or race. There was evidence that the effect of
standardised vitamin D on the cumulative incidence of
Fig. 1 The distribution of standardised cord blood
25(OH)D concentrations
Table 2 Characteristics of participants and standardised vitamin D (25OH) D) concentrations
Characteristic 25 (OH) D nmol/La N <25 nmol/L 25–49.9 nmol/L 50–74.9 nmol/L ≥75 nmol/L
Total cohort 57.0 ± 24.1 270 (100) 19 (7.0) 97 (35.9) 103 (38.2) 51 (18.9)
Treatment group
Control 56.9 ± 24.5 140 (51.9) 11 (7.9) 47 (33.6) 55 (39.3) 27 (19.3)
DHA 57.2 ± 23.8 130 (48.1) 8 (6.2) 50 (38.5) 48 (36.9) 24 (18.5)
Mother smoked during or leading up to pregnancy
Yes 54.7 ± 21.7 73 (27.0) 6 (8.2) 28 (38.9) 28 (38.9) 11 (15.1)
No 57.9 ± 24.9 197 (73.0) 13 (6.6) 69 (35.0) 75 (38.1) 40 (20.3)
Parity
0 55.4 ± 25.7 110 (40.7) 11 (10.0) 40 (36.4) 39 (35.5) 20 (18.2)
> = 1 58.2 ± 23.0 160 (59.3) 8 (5.0) 57 (35.6) 64 (40.0) 31 (19.4)
Infant sex
Male 59.0 ± 26.0 129 (47.8) 7 (5.4) 44 (34.1) 52 (40.3) 26 (20.2)
Female 55.2 ± 22.2 141 (52.2) 12 (8.5) 53 (37.6) 51 (36.2) 25 (17.7)
Values are numbers (percentages) unless indicated otherwise
DHA Docosahexaenoic acid
a Mean ± SD all such values
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any sensitisation by 3 years of age was modified by
mother’s smoking status (interaction p-value = 0.03). A
10 nmol/L increase in standardised cord blood 25(OH)
concentration was associated with a 9 % reduction in the
risk of any sensitisation at 1 or 3 years in children whose
mother did not smoke during or leading up to pregnancy
(RR = 0.91; 95 % CI 0.82, 1.00). In contrast, for children
with a mother that did smoke, a 10 nmol/L increase in
cord blood 25(OH)D concentration was associated with
an 11 % increase in the risk of any sensitisation at 1 or
3 years (RR = 1.11; 95 % CI 0.96, 1.28). No evidence of
effect modification was found for any other allergic dis-
ease outcomes.
Discussion
Our results of a 10 nmol/L rise in standardised cord
blood 25(OH)D concentration being associated with re-
duced risk of eczema are consistent with the findings of
other observational studies, which have also reported
that higher cord blood 25(OH)D concentrations are as-
sociated with decreased risk of eczema [4, 6]. There have
also been recent studies [15, 24, 25] which have found
no association with cord blood 25(OH)D concentration
and eczema outcomes in early childhood. Interestingly,
our study also found that the cumulative incidence of
eczema with sensitisation by 3 years of age was also
associated with cord blood 25(OH)D concentration. Pre-
vious other studies investigating cord blood 25(OH)D
concentrations have not reported results for atopic ec-
zema (eczema with confirmed sensitisation). Other studies
have reported food and/or inhalant allergen sensitisation
independent of allergic disease outcomes and in accord-
ance with our findings most [6, 24, 25] have found no
association of cord blood 25(OH)D concentration with
child sensitisation status. However Rothers et al. [26] in
the United States identified a U-shaped relationship
with lower (< 50 nmol/L) and higher (> 100 nmol/L) cord
blood 25(OH)D concentrations associated with increased
inhalant allergen sensitisation.
There are several biological pathways which may
account for a beneficial effect of vitamin D in reducing
eczema risk. The pathogenesis of eczema involves im-
mune dysregulation, altered epidermal barrier function
and inadequate bacterial defence [27] and vitamin D is
known to have a regulatory influence on all of these
[28]. Thus, vitamin D deficiency in early life is a strong
Table 3 Associations between standardised vitamin D (25 (OH) D) levels and allergic disease outcomes
Allergic disease outcome Incidencea Unadjusted





Eczema at 1 year of age 70/265 (26.4) 0.89 (0.81, 0.97) 0.88 (0.81, 0.96) 0.002
Eczema with sensitisation at 1 year of age 19/265 (7.2) 0.85 (0.70, 1.04) 0.84 (0.69, 1.01) 0.07
Eczema at 3 years of age 77/247 (31.2) 0.94 (0.87, 1.01) 0.93 (0.86, 1.01) 0.07
Eczema with sensitisation at 3 years of age 26/244 (10.7) 0.87 (0.74, 1.02) 0.85 (0.73, 1.00) 0.051
Cumulative incidence of eczema by 3 years of age 101/250 (40.4) 0.92 (0.86, 0.98) 0.92 (0.86, 0.97) 0.005
Cumulative incidence of eczema with sensitisation by 3 years of age 30/243 (12.3) 0.85 (0.73, 0.98) 0.83 (0.72, 0.96) 0.01
IgE-mediated food allergy at 1 year of age 4/260 (1.5) 0.60 (0.41, 0.90) - 0.01d
IgE-mediated food allergy at 3 years of age 7/229 (3.1) 0.78 (0.54, 1.13) 0.77 (0.50, 1.17) 0.22
Cumulative incidence IgE-mediated food allergy by 3 years of age 8/228 (3.5) 0.80 (0.57, 1.12) 0.78 (0.55, 1.11) 0.17
Any sensitisation at 1 year of age 36/260 (13.8) 0.95 (0.84, 1.09) 0.94 (0.83, 1.07) 0.36
Any sensitisation at 3 years of age 52/229 (22.7) 0.96 (0.87, 1.07) 0.95 (0.86, 1.05) 0.28
Cumulative incidence any sensitisation by 3 years of age 66/230 (28.7) 0.96 (0.88, 1.05) 0.95 (0.87, 1.03) 0.23
Cumulative incidence of allergic rhinitis by 3 years of age 39/246 (15.9) 0.97 (0.86, 1.10) 0.98 (0.87, 1.11) 0.80
Cumulative incidence of allergic rhinitis with sensitisation by 3 years of age 13/245 (5.3) 0.95 (0.75, 1.19) 0.94 (0.75, 1.18) 0.60
Cumulative incidence of asthma by 3 years of age 32/248 (12.9) 1.03 (0.91, 1.17) 1.03 (0.90, 1.18) 0.67
Cumulative incidence of asthma with sensitisation by 3 years of age 5/245 (2.0) 1.05 (0.74, 1.48) - 0.80d
Cumulative incidence of any allergic disease by 3 years of age 137/240 (57.1) 0.95 (0.90, 0.99) 0.95 (0.90, 0.99) 0.02
Cumulative incidence of any allergic disease with sensitisation by 3 years of age 40/228 (17.5) 0.88 (0.78, 1.00) 0.87 (0.77, 0.98) 0.03
Respiratory tract infections by 1 year of age 45/267 (16.9) 1.08 (0.98, 1.20) 1.07 (0.97, 1.18) 0.18
Cumulative incidence of respiratory tract infections by 3 years of age 70/250 (28.0) 1.03 (0.95, 1.11) 1.02 (0.95, 1.10) 0.61
RR Relative risk
a Values are numbers (percentages)
b Relative Risk of outcome corresponding to a 10 unit increase in standardised 25(OH)D
c Adjusted for treatment group, parity, gender and maternal smoking during or leading up to pregnancy
d Unadjusted p-value reported due to low incidence of outcome
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candidate for predisposition to eczema. These biological
effects are in keeping with observational studies that
have indicated a link between vitamin D status and
eczema outcomes, including lower serum vitamin D
concentrations associated with increased incidence and
severity of eczema symptoms [29].
We also found that higher cord blood 25(OH)D concen-
trations were associated with decreased risk of develop-
ment of IgE-mediated food allergy in infancy. However
this result should be interpreted with caution due to the
low incidence of medically diagnosed IgE-mediated food
allergy at 1 year of age (1.5 %) in our cohort. Our inci-
dence was substantially lower than that reported in
another recent Australian cohort, where food challenges
identified > 10 % of 1 year olds to have IgE-mediated food
allergy [30]. The inability to perform food challenges (due
to insufficient resources) may explain the lower incidence
of IgE-mediated food allergy at 1 year of age in our cohort.
In contrast, a cohort study by Weisse et al. [15] found
higher maternal blood (34 weeks gestation) as well as cord
blood 25(OH)D concentrations to be associated with
increased risk of parent reported doctor diagnosed food
allergy, with an incidence of 5.5 % by 2 years of age.
Whereas other studies [6, 25] have found no association
of cord blood 25(OH)D concentrations with the develop-
ment of food allergy. Interestingly, the Weisse et al. [15]
German cohort study was conducted at a higher latitude
of 510 N (compared to our study at 350S) with lower
median (inter-quartile range) cord blood concentration of
27 nmol/L (17–43 nmol/L). These lower average cord
blood concentrations may have contributed to their
contrasting finding with regard to food allergy outcomes
and the finding of no association with offspring eczema
outcomes.
The pattern of allergic disease is known to differ with
age, with the greatest incidence of food allergy and atopic
dermatitis/eczema being in the first few years of life, while
asthma and allergic rhinitis continue to rise until adult-
hood. Consistent with the recent findings of other cohort
studies, we found no association of cord blood 25(OH)D
concentrations with asthma [4, 5, 24, 26] or allergic rhin-
itis [4, 5, 24, 26] outcomes. We acknowledge that longer
term follow-up of these children is needed before this
result can be conclusive and we are currently following up
the children in our cohort at 6 years of age for allergic
disease outcomes.
The strengths of our study include standardised medical
assessments of allergic disease outcomes, with high follow
up rates of > 95 % at 1 year and > 90 % at 3 years of age.
We also calculated and reported standardised cord blood
25(OH)D concentrations for our results, which is import-
ant to adjust for seasonal variability in 25(OH)D concen-
trations due to month of birth. We acknowledge that a
limitation of our study was that we have not taken blood
samples from the children to examine vitamin D status at
multiple time-points during early life. It may be that the
timing of differential vitamin D status could have variable
effects on the development of allergic diseases. A family
history of allergic disease in all the participants in our
study may reduce the ability to generalize our findings to
the whole population, however Biaz et al. [4] who did not
select participants based on a family history of allergic
disease also reported that higher cord blood 25(OH)D
concentrations were associated with decreased risk of
early childhood eczema. Another possible limitation to
the generalisability of our results was that we had a pre-
dominance of Caucasian mothers (95 %). Since Caucasian
mothers were found to have higher cord blood 25(OH)D
concentrations compared to non-Caucasian mothers,
replication of our investigations would be beneficial in
study populations with a predominance of non-Caucasian
participants.
There are several randomised controlled trials currently
investigating the effect of maternal vitamin D supplemen-
tation during pregnancy on allergic disease outcomes
(NCT00920621 and NCT00856947). The level of supple-
mentation tested in these trials should be adequate to
attain a significant shift in maternal 25(OH)D levels and
therefore provide definitive evidence regarding the effect
of vitamin D during pregnancy on early childhood allergic
disease.
Conclusion
In children with a family history of allergic disease, higher
cord blood 25(OH)D concentrations appear to be associ-
ated with a reduction in the risk of eczema development
through to 3 years of age.
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